The Company did not have sufficient cancer cases to finish the clinical study in accordance with the requirements of its independent bio-statistician. The clinical study participants were not from a pre-selected patient population. Therefore, the Company did not know whether the patients had cancer or did not have cancer before they participated in the clinical study. The cancer rate did not decline during the period.""